Immatics (IMTX)
Develops PRAME-focused cancer therapies with cell therapy and TCR bispecific programs.
$8.80
vs last close+0.08 (+0.88%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 74.44% | 99.80M ADS | |
|---|---|---|---|
| 85 holders · as of Jun 30, 2026 | |||
| Insiders | 0.54% | 718.6K ADS | |
| 7 holders · as of Mar 18, 2026 | |||
| Other | 25.02% | 33.55M ADS | |
| remainder | |||
134.07M ADS as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
85 holders · 99.80M shares · 12 new positions · 37 increased · 33 reduced · 13 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 22.37M | 16.68% | +712.9K | Aug 14, 2026 |
| RTW Investments, LP | 12.95M | 9.66% | +76.8K | Aug 14, 2026 |
| Suvretta Capital Management, LLC | 11.19M | 8.35% | 0 | Aug 14, 2026 |
| Perceptive Advisors LLC | 10.38M | 7.74% | 0 | Aug 14, 2026 |
| Baker Bros. Advisors LP | 9.51M | 7.09% | −1.41M | Aug 14, 2026 |
| Jefferies Financial Group Inc. | 6.51M | 4.85% | +1.45M | Aug 17, 2026 |
| Vestal Point Capital, LP | 6.18M | 4.61% | 0 | Aug 14, 2026 |
| Sofinnova Investments, Inc. | 3.67M | 2.74% | +38.9K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 16.10% | 21.65M | 13G | May 15, 2026 |
| Baker Bros. Advisors LP | 9.95% | 12.09M | 13G | Nov 14, 2025 |
| RTW Investments, LP | 9.60% | 12.87M | 13G | May 15, 2026 |
| Suvretta Capital Management, LLC | 8.30% | 11.19M | 13G | Feb 13, 2026 |
| Perceptive Advisors LLCincl. Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. | 7.90% | 9.47M | 13D/A | Oct 17, 2024 |
| The Toronto-Dominion Bank | 5.50% | 7.44M | 13G | May 15, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 26, 2026 | Perceptive Advisors LLCdirector | Purchase | 863,060 | $8.69 | 11,246,516 |
House and Senate disclosures
Not reported.